2025 年 42 巻 3 号 p. 262-266
With advances in symptomatic therapy, many patients with Parkinson disease (PD) are now able to fulfill their lives. On the other hand, as the disease progresses, most of patients become demented as well as a decline in dopamine responsiveness. Thus, the development of disease–modifying therapy (DMT) to halt the progression of the disease is mandatory. At the beginning of 2024, about 60 DMT trials are underway for PD, and these trials are classified in terms of mechanism of action as follows : (1) those targeting α–synuclein (αS), which is thought to be the key to neurodegeneration, (2) those targeting other PD–related molecules such as LRRK2 (leucine–rich repeat kinase 2), and (3) drugs that target neuroprotective effects. Among these, antibody therapies targeting inhibition of αS cell–to–cell transmission and glucagon–like peptide–1 (GLP–1) receptor agonists, which have been shown to be cytoprotective as drug repositioning agents for diabetes mellitus, have attracted much attention. In this article, I will introduce the current status of DMT development for PD and discuss future issues.
